AU Patent

AU2022268464B2 — Nitrogen-containing heterocyclic pyridine compound

Assigned to Shanghai Zheye Biotechnology Co Ltd · Expires 2025-04-17 · 1y expired

What this patent protects

A nitrogen-containing heterocyclic protein inhibitor compound, and a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. Also provided are a preparation method for the nitrogen-containing heterocyclic compound, and a use thereof. A drug prepared from the compo…

USPTO Abstract

A nitrogen-containing heterocyclic protein inhibitor compound, and a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. Also provided are a preparation method for the nitrogen-containing heterocyclic compound, and a use thereof. A drug prepared from the compound is widely used for treating diseases, the diseases comprising multiple types of autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, lupus erythematosus, neurodermatitis, dermatitis, psoriasis, psoriatic arthritis, Crohn's disease, dry syndrome, and scleroderma.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022268464B2
Jurisdiction
AU
Classification
—
Expires
2025-04-17
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Zheye Biotechnology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.